Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey

Antonin Levy*, Lizza E. L. Hendriks, Cecile Le Pechoux, Sally Falk, Benjamin Besse, Silvia Novello, Anne-Marie C. Dingemans, Baktiar Hasan, Martin Reck, Thierry Berghmans, Corinne Faivre-Finn, EORTC LCG

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)145-147
Number of pages3
JournalLung Cancer
Volume136
DOIs
Publication statusPublished - Oct 2019
Event38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO) - Barcelona, SPAIN, Milan, Italy
Duration: 26 Apr 201930 Apr 2019
Conference number: 37

Keywords

  • Small-cell lung cancer
  • Limited-stage
  • Thoracic radiotherapy
  • Fractionation
  • THORACIC RADIOTHERAPY
  • IRRADIATION

Cite this

Levy, A., Hendriks, L. E. L., Le Pechoux, C., Falk, S., Besse, B., Novello, S., Dingemans, A-M. C., Hasan, B., Reck, M., Berghmans, T., Faivre-Finn, C., & EORTC LCG (2019). Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. Lung Cancer, 136, 145-147. https://doi.org/10.1016/j.lungcan.2019.08.007